-
www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/2014chartbooks/hispanichealth/2014nhqdr-hispanichealth-pt3.pptx
September 19, 2015 - most effective prevention and treatment practices for the leading causes of mortality, starting with cardiovascular
-
hcup-us.ahrq.gov/reports/statbriefs/sb245-Substance-Inpatient-Stays-Across-US-Counties.pdf
February 01, 2018 - substance use disorder are at
greater risk of major medical conditions and adverse outcomes
such as cardiovascular
-
hcup-us.ahrq.gov/reports/methods/2008_07.pdf
January 01, 2008 - Examples include: health status, immunization, diabetes, tobacco use, HIV/AIDS,
arthritis, asthma, and cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/2022qdr-appendix-combined.pdf
October 25, 2022 - • From 2000 to 2020, 83% of cancer measures, 14% of cardiovascular disease measures, 20%
of chronic … • From 2000 to 2020, 14% of cardiovascular disease measures, 14% of diabetes measures, and
60% of mental
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/s9Hht_QpMB4gQg26rTpcaN
November 01, 2013 - Comparative cardiovascular safety of dementia medications: a cross-national
study. … decline (i.e., donepezil, galantamine, rivastigmine, and memantine) and medications primarily aimed at cardiovascular
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/indirect-comparisons_research.pdf
March 01, 2013 - of
extended-release oxybutynin
or Tolterodine would present
undue risk (medically
uncontrolled cardiovascular … agents or drugs for the
treatment of Parkinson’s
disease, anti-arrhythmic),
serious life threatening
cardiovascular
-
hcup-us.ahrq.gov/db/nation/neds/stats/NEDS_2015Q1Q3_IP_MaskedStats.PDF
October 01, 2014 - 0.04
61: Other OR procedures on vessels other than head and neck 21,604 0.68
62: Other diagnostic cardiovascular … procedures 1,475 0.05
63: Other non-OR therapeutic cardiovascular procedures 11,786 0.37
64: Bone
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-surgery-preparation_executive.pdf
April 01, 2014 - of adverse effects of OMBP are the elderly
(≥65 years of age) and those with comorbidities such as
cardiovascular
-
effectivehealthcare.ahrq.gov/sites/default/files/cultural-competence_disposition-comments.pdf
January 01, 2020 - risk
factors and social determinants of health related to chronic
conditions such as diabetes and cardiovascular
-
hcup-us.ahrq.gov/db/nation/nass/2017_NASS_Introduction.pdf
January 01, 2017 - dialysis
061 Other OR procedures on vessels other than head and neck
063 Other non-OR therapeutic cardiovascular
-
digital.ahrq.gov/sites/default/files/docs/publication/u18hs016394-lapane-final-report-2006.pdf
January 01, 2006 - notification that a patient has NOT picked up a prescription, more than half
of clinicians indicated that cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/2014chartbooks/hispanichealth/2014nhqdr-hispanichealth-pt3.pdf
June 01, 2014 - most effective prevention and treatment practices for the leading causes of
mortality, starting with cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-131-fullreport.pdf
April 05, 2017 - example, a measure
addressing childhood obesity may have implications for the subsequent development
of cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-145-fullreport.pdf
July 01, 2016 - example, a measure
addressing childhood obesity may have implications for the subsequent development
of cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-195-fullreport.pdf
December 17, 2019 - example, a measure
addressing childhood obesity may have implications for the subsequent development
of cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-5.pdf
February 02, 2012 - Cardiovascular monitor-
ing and stimulant drugs for attention-
deficit/hyperactivity disorder.
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/preventive/chipra-202-fullreport.pdf
January 01, 2014 - example, a measure
addressing childhood obesity may have implications for the subsequent development
of cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-136-fullreport.pdf
July 01, 2018 - example, a measure
addressing childhood obesity may have implications for the subsequent development
of cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-144-fullreport.pdf
January 01, 2020 - example, a measure
addressing childhood obesity may have implications for the subsequent development
of cardiovascular
-
www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-measure-1-section-5-attachment-5.pdf
February 02, 2012 - Cardiovascular monitor
ing and stimulant drugs for attention
deficit/hyperactivity disorder.